NRT.AX - Kazia Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD

Kazia Therapeutics Limited

20 George Street
Level 5
Hornsby, NSW 2077
61 2 9472 4100

IndustryDrugs - Generic
Full-time employees

Key executives

Dr. James Garner M.A., MBA, MBBS, B.Sc (Hons), SAFin.CEO, MD & Exec. Director565.21kN/A44
Ms. Gabrielle Heaton BBUS (ACC), CPADirector of Fin. & Admin.61.3kN/AN/A
Dr. Peng Leong MBA, Ph.D.Chief Bus. Officer438.53kN/AN/A
Dr. Gordon Hirsch MBA, MBBCh, FCP(SA), BSc HonsChief Medical Officer258.24kN/AN/A
Ms. Catherine Hill ACA, GAICD, BSc (Hons)Company Sec.113.2kN/AN/A
Amounts are as of 31December,2017, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Novogen Limited, a biotechnology company, develops anti-cancer drugs. The company has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. It is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. The company has collaboration agreement with The University of York, The Children’s Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. Novogen Limited was founded in 1994 and is headquartered in Hornsby, Australia.

Corporate governance

Kazia Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.